RWM
FULC icon

Rialto Wealth Management’s Fulcrum Therapeutics FULC Stock Holding History

Rialto Wealth Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$582 Hold
159
– – ﹤0.01% 1600
2026
Q1 		$1.22K Hold
159
– – ﹤0.01% 1037
2025
Q4 		$1.8K Hold
159
– – ﹤0.01% 783
2025
Q3 		$1.46K Hold
159
– – ﹤0.01% 773
2025
Q2 		$1.09K Hold
159
– – ﹤0.01% 819
2025
Q1 		$458 Buy
+159
New +$584 ﹤0.01% 933

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rialto Wealth Management's FULC Position: Q2 2026 in Review

Rialto Wealth Management held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 159 shares worth $582. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Rialto Wealth Management first reported a position in FULC in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.8K in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Rialto Wealth Management held 159 shares of Fulcrum Therapeutics worth $582 as of Q2 2026.
  • Rialto Wealth Management left its Fulcrum Therapeutics share count unchanged in Q2 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1600 holding.
  • Rialto Wealth Management first reported a position in Fulcrum Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Rialto Wealth Management's Fulcrum Therapeutics position peaked at $1.8K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.